# Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma

> **NCT03168061** · PHASE1,PHASE2 · UNKNOWN · sponsor: **NanoCarrier Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Solid Tumor
- Soft Tissue Sarcoma
- Metastatic Sarcoma
- Sarcoma

## Interventions

- **DRUG:** NC 6300

## Key facts

- **NCT ID:** NCT03168061
- **Lead sponsor:** NanoCarrier Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-06-30
- **Primary completion:** 2020-07
- **Final completion:** 2020-07
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2020-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03168061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03168061, "Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03168061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*